MedPath

Potassium

Generic Name
Potassium
Drug Type
Small Molecule
Chemical Formula
K
CAS Number
7440-09-7
Unique Ingredient Identifier
RWP5GA015D
Background

Potassium is an essential nutrient, like Calcium and Magnesium. It was identified as a shortfall nutrient by the 2015-2020 Advisory Committee of Dietary Guidelines for Americans. Many conditions and diseases interfere with normal body potassium balance, and underconsumption of potassium is one example. Hypokalemia (low potassium) or hyperkalemia (high potassium) may result, manifesting as various signs and symptoms. Some examples of potassium-related complications include life-threatening arrhythmia, neuromuscular dysfunction, diarrhea, nausea, and vomiting.

Various pharmacological preparations have been formulated to replenish potassium. They are available in an assortment of tablet, injection, and other forms, depending on the setting and condition being treated. Potassium is often a key ingredient for intravenous fluids, given to patients in clinical settings for rehydration, nutrition, and replenishment of electrolytes. Examples of potassium formulations include potassium citrate, potassium chloride, and potassium with dextrose and sodium chloride.

Indication

General uses of potassium

Potassium is indicated to treat a variety of conditions. Firstly, it used to replenish potassium that has been depleted by conditions including but not limited to malabsorption, decreased intake, or excess sodium intake. The causes of potassium deficiency are numerous. The following indications for potassium are not comprehensive, but include the main indications for which this nutrient is used. Various products and preparations contain potassium.

Potassium chloride

Potassium chloride is one of the main preparations of potassium used in a clinical setting. The oral solution is indicated for the prevention and treatment of hypokalemia presenting with or without metabolic alkalosis, in patients who have failed conservative management with potassium-rich foods or diuretic dose titrations. The injection form of potassium chloride is indicated to replenish potassium in patients who are not feasible candidates for oral potassium. Highly concentrated potassium is intended for the treatment of potassium deficiency in fluid restricted individuals who cannot tolerate fluid volumes normally associated with injected potassium solutions that contain lower concentrations.

Finally, the extended-release tablet preparation of potassium chloride is used to treat hypokalemia with or without metabolic alkalosis, to treat digitalis intoxication, and to manage patients with hypokalemic familial periodic paralysis. It is also used in the prevention of hypokalemia in those who are at a high risk of negative clinical outcomes if hypokalemia occurs; patients on digitalis or those with cardiac arrhythmias would be at particular risk of negative outcomes.

Potassium chloride with dextrose and sodium chloride

This liquid preparation is is indicated in a clinical setting as a source of water, calories and electrolytes. Potassium acetate solution is meant as an alternative to potassium chloride, replenishing potassium and added to large volume infusion fluids for intravenous injection.

Potassium citrate

The potassium citrate preparation is used for the management of renal tubular acidosis (RTA) with calcium stones (nephrolithiasis); calcium oxalate stones by any cause, and uric acid nephrolithiasis (with or without calcium stones). This regimen also includes adequate water intake (leading to a urine out put of 2 L/day or more) and sodium restriction.

Associated Conditions
Caloric Intake, Electrolyte and fluid balance conditions, Hydration, Hypokalemia, Potassium

Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair

First Posted Date
2023-09-15
Last Posted Date
2023-09-15
Lead Sponsor
China National Center for Cardiovascular Diseases
Target Recruit Count
164
Registration Number
NCT06039592
Locations
🇨🇳

Fuwai hospital, Beijing, Beijing, China

Study of Drug Therapy for Pediatric Heart Failure

First Posted Date
2023-09-15
Last Posted Date
2023-09-15
Lead Sponsor
China National Center for Cardiovascular Diseases
Target Recruit Count
200
Registration Number
NCT06039540
Locations
🇨🇳

Fuwai hospital, Beijing, Beijing, China

Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation

First Posted Date
2023-09-14
Last Posted Date
2023-09-15
Lead Sponsor
China National Center for Cardiovascular Diseases
Target Recruit Count
122
Registration Number
NCT06037434
Locations
🇨🇳

Fuwai hospital, Beijing, Beijing, China

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2
Recruiting
Conditions
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
First Posted Date
2023-07-27
Last Posted Date
2023-11-18
Lead Sponsor
Akeso
Target Recruit Count
90
Registration Number
NCT05960955
Locations
🇨🇳

Tianjin Provincial Tumor Hospital, Tianjin, China

Bone in CKD Alkali Response (BICARb Pilot Trial)

Phase 2
Recruiting
Conditions
Chronic Kidney Diseases
Bone Loss
Interventions
First Posted Date
2023-06-26
Last Posted Date
2024-10-15
Lead Sponsor
Albert Einstein College of Medicine
Target Recruit Count
103
Registration Number
NCT05918029
Locations
🇺🇸

Albert Einstein College of Medicine, Bronx, New York, United States

🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Doxycycline for Helicobacter Pylori Rescue Treatment

Phase 4
Recruiting
Conditions
Helicobacter Pylori Infection
Interventions
First Posted Date
2023-05-25
Last Posted Date
2024-12-30
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
368
Registration Number
NCT05874570
Locations
🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

Rescue Therapy for Helicobacter Pylori Infection

First Posted Date
2023-05-25
Last Posted Date
2024-12-30
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
360
Registration Number
NCT05874544
Locations
🇨🇳

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

🇨🇳

Shanghai Songjiang District Central Hospital, Shanghai, Shanghai, China

🇨🇳

The Second Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, Zhejiang, China

Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection

First Posted Date
2023-05-12
Last Posted Date
2025-03-25
Lead Sponsor
TenNor Therapeutics (Suzhou) Limited
Target Recruit Count
700
Registration Number
NCT05857163
Locations
🇨🇳

Peking University Third Hospital, Beijing, China

Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus

Phase 3
Recruiting
Conditions
Intracardiac Thrombus
Heart Failure
STEMI
Interventions
Drug: Direct oral anticoagulant
First Posted Date
2023-04-24
Last Posted Date
2024-07-23
Lead Sponsor
Centre Hospitalier Universitaire de Nīmes
Target Recruit Count
340
Registration Number
NCT05825573
Locations
🇫🇷

CH Compiègne Noyon, Compiègne, France

🇫🇷

CHU Angers, Angers, France

🇫🇷

CH Chartres, Chartres, France

and more 32 locations

Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial

Phase 4
Not yet recruiting
Conditions
Helicobacter Pylori Infection
Interventions
First Posted Date
2023-02-14
Last Posted Date
2023-02-14
Lead Sponsor
Shanghai East Hospital
Target Recruit Count
100
Registration Number
NCT05726734
Locations
🇨🇳

Shanghai East Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath